Trial Profile
A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys), With and Without Ribavirin (Copegus) in Subjects With Hepatitis C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PROVE-2
- Sponsors Vertex Pharmaceuticals
- 24 Sep 2009 A pooled analysis of data from the PROVE 1 and PROVE 2 trials will be presented in a poster session at AASLD 2009 on Nov 3rd.
- 12 May 2009 Actual end date (1 Jun 2008) added as reported by ClinicalTrials.gov.
- 30 Apr 2009 Primary endpoint results published in New England Journal of Medicine 360: 1839-1850, No. 18, 30 Apr 2009.